JP2016513691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513691A5 JP2016513691A5 JP2016502396A JP2016502396A JP2016513691A5 JP 2016513691 A5 JP2016513691 A5 JP 2016513691A5 JP 2016502396 A JP2016502396 A JP 2016502396A JP 2016502396 A JP2016502396 A JP 2016502396A JP 2016513691 A5 JP2016513691 A5 JP 2016513691A5
- Authority
- JP
- Japan
- Prior art keywords
- topical
- composition
- eye
- region
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 110
- 239000000203 mixture Substances 0.000 claims 84
- 230000000699 topical effect Effects 0.000 claims 84
- 229960003387 progesterone Drugs 0.000 claims 55
- 239000000186 progesterone Substances 0.000 claims 55
- 210000000744 eyelid Anatomy 0.000 claims 30
- 229930003827 cannabinoid Natural products 0.000 claims 28
- 239000003557 cannabinoid Substances 0.000 claims 28
- 230000001815 facial effect Effects 0.000 claims 19
- 239000004599 antimicrobial Substances 0.000 claims 8
- 208000019505 Deglutition disease Diseases 0.000 claims 5
- 229940065144 cannabinoids Drugs 0.000 claims 5
- 244000005700 microbiome Species 0.000 claims 5
- 230000000508 neurotrophic effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 3
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 3
- 239000002249 anxiolytic agent Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 208000010217 blepharitis Diseases 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 206010013932 dyslexia Diseases 0.000 claims 2
- 210000004709 eyebrow Anatomy 0.000 claims 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 2
- 210000004175 meibomian gland Anatomy 0.000 claims 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000003508 Botulism Diseases 0.000 claims 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011026 Corneal lesion Diseases 0.000 claims 1
- 206010054760 Corneal thinning Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000004929 Facial Paralysis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010048462 Growth of eyelashes Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 208000026680 Metabolic Brain disease Diseases 0.000 claims 1
- 206010062190 Metabolic encephalopathy Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003423 Mucocele Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010052143 Ocular discomfort Diseases 0.000 claims 1
- 208000023715 Ocular surface disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims 1
- 206010037508 Punctate keratitis Diseases 0.000 claims 1
- 201000001949 Retinal Vasculitis Diseases 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 206010005159 blepharospasm Diseases 0.000 claims 1
- 230000000744 blepharospasm Effects 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960000724 cidofovir Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 229960000735 docosanol Drugs 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 206010015907 eye allergy Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 210000000720 eyelash Anatomy 0.000 claims 1
- 229960004396 famciclovir Drugs 0.000 claims 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims 1
- 210000001061 forehead Anatomy 0.000 claims 1
- 229960005102 foscarnet Drugs 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical group O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000011977 language disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000002276 neurotropic effect Effects 0.000 claims 1
- 201000005111 ocular hyperemia Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims 1
- 229960001179 penciclovir Drugs 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000007847 structural defect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000006379 syphilis Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229960002149 valganciclovir Drugs 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790120P | 2013-03-15 | 2013-03-15 | |
| US61/790,120 | 2013-03-15 | ||
| PCT/US2014/027280 WO2014152385A2 (en) | 2013-03-15 | 2014-03-14 | Cranial delivery of pharmaceuticals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513691A JP2016513691A (ja) | 2016-05-16 |
| JP2016513691A5 true JP2016513691A5 (https=) | 2017-02-16 |
| JP6317805B2 JP6317805B2 (ja) | 2018-04-25 |
Family
ID=51581702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502396A Active JP6317805B2 (ja) | 2013-03-15 | 2014-03-14 | 局所用プロゲステロン組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9682032B2 (https=) |
| EP (1) | EP2968368B1 (https=) |
| JP (1) | JP6317805B2 (https=) |
| CN (1) | CN105188708B (https=) |
| AU (1) | AU2014239842B2 (https=) |
| BR (1) | BR112015023694B1 (https=) |
| CA (1) | CA2909490C (https=) |
| ES (1) | ES2649730T3 (https=) |
| HU (1) | HUE034886T2 (https=) |
| MX (1) | MX2015013186A (https=) |
| PT (1) | PT2968368T (https=) |
| TW (1) | TWI636785B (https=) |
| WO (1) | WO2014152385A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202011669PA (en) | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| US10456435B2 (en) | 2015-07-15 | 2019-10-29 | Christopher A. MCELVANY | Topical antiviral formulations and methods of using the same |
| CN110072523A (zh) * | 2016-09-07 | 2019-07-30 | 格利亚有限责任公司 | 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状 |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| CN109172580B (zh) * | 2018-09-06 | 2021-04-27 | 中山万汉制药有限公司 | 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12472158B2 (en) | 2019-02-27 | 2025-11-18 | Vanderbilt University | Methods of treating trigeminal nerve pain |
| WO2021163253A1 (en) * | 2020-02-12 | 2021-08-19 | Glia, Llc | Progesterone combinations |
| JP2025512495A (ja) | 2022-04-12 | 2025-04-17 | シャッケルフォード・ファーマ・インコーポレーテッド | 発作性障害の治療 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766988B2 (en) * | 1998-04-21 | 2003-10-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cannabinoids as antioxidants and neuroprotectants |
| US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| US20040037895A1 (en) | 2002-08-23 | 2004-02-26 | Alex Zhu | Methods of treating involuntary facial spasms and facial wrinkles |
| US20060089408A1 (en) | 2004-10-22 | 2006-04-27 | Wei Ted C Jr | Method of treating blepharospasm with a prostaglandin derivative |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| US8222292B2 (en) * | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| EP2214482A4 (en) | 2007-10-31 | 2011-08-24 | Pamela Lipkin | COMPOSITIONS OF PROSTAGLANDIN ANALOGUES AND METHODS OF TREATING EPITHELIAL STATES |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| US8236768B2 (en) | 2008-10-03 | 2012-08-07 | 3B Pharmaceuticals, Inc. | Topical antiviral formulations |
| WO2011055383A2 (en) | 2009-11-06 | 2011-05-12 | Lyka Labs Limited | Intranasal delivery to improve the performance of children suffering from dyslexia |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| PT2877184T (pt) | 2012-07-27 | 2019-12-02 | Glia Llc | Composições e tratamento para doenças e distúrbios oculares |
-
2014
- 2014-03-14 ES ES14768223.1T patent/ES2649730T3/es active Active
- 2014-03-14 WO PCT/US2014/027280 patent/WO2014152385A2/en not_active Ceased
- 2014-03-14 CA CA2909490A patent/CA2909490C/en active Active
- 2014-03-14 AU AU2014239842A patent/AU2014239842B2/en active Active
- 2014-03-14 HU HUE14768223A patent/HUE034886T2/hu unknown
- 2014-03-14 TW TW103109706A patent/TWI636785B/zh active
- 2014-03-14 MX MX2015013186A patent/MX2015013186A/es active IP Right Grant
- 2014-03-14 BR BR112015023694-4A patent/BR112015023694B1/pt active IP Right Grant
- 2014-03-14 EP EP14768223.1A patent/EP2968368B1/en active Active
- 2014-03-14 CN CN201480024402.3A patent/CN105188708B/zh active Active
- 2014-03-14 JP JP2016502396A patent/JP6317805B2/ja active Active
- 2014-03-14 US US14/777,278 patent/US9682032B2/en active Active
- 2014-03-14 PT PT147682231T patent/PT2968368T/pt unknown
-
2017
- 2017-06-20 US US15/627,894 patent/US10251835B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513691A5 (https=) | ||
| Nickla et al. | Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning | |
| JP6317805B2 (ja) | 局所用プロゲステロン組成物 | |
| IL274234B2 (en) | Compositions and methods for the treatment of eye disorders | |
| EP3416617B1 (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| RU2020119228A (ru) | Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи | |
| CN102670493B (zh) | 盐酸洛美沙星滴眼液及其制备方法与应用 | |
| RU2017111579A (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| Agarwal et al. | Textbook on clinical ocular pharmacology & therapeutics | |
| MX2021006642A (es) | Compuestos y composiciones para tratamientos oculares. | |
| Haberer et al. | Anestesia in oftalmologia | |
| Barai et al. | Computer vision syndrome: Causes, symptoms and management in the pharmacy | |
| Richa et al. | Promising implication of ocuserts in ocular disease | |
| Thomas et al. | Ophthalmic Considerations in Stevens-Johnson Syndrome | |
| Hase et al. | Using Corneal Collagen Cross-Linking in the Treatment of Keratoconus | |
| Ittner | Nutritional Optic Neuropathy as Result of Topiramate-Induced Appetite Suppression | |
| Bivens et al. | Acute painless vision loss in a young person | |
| Pagare et al. | To study the efficacy of Yashtimadhu kwath aashchontana in simple hyperaemia of conjunctiva WSR Sirotpata | |
| Makogon et al. | Dry eye masky syndrome: degree of expression and possibilities of correction | |
| Vishnoi et al. | EMERGING LIFE STYLE DISORDERS IN COVID ERA WSR TO VISUAL DISPLAY TERMINAL SYNDROME AND AYURVEDA | |
| Gazepov et al. | Unwanted side effects of travoprost | |
| Lee et al. | A case of toxic keratitis due to chronic use of sodium hyaluronate eyedrops | |
| Groves et al. | Therapeutic options expand. | |
| JP2014222293A (ja) | 視野遮蔽器具 | |
| Katsimpris | Acute angle closure glaucoma and anterior uveitis: case report |